LI-RADS v2018: utilizing ancillary features on gadoxetic acid-enhanced MRI to improve the diagnostic performance of small hapatocellular carcinoma (≤ 20 mm)

[1] Lim K(2022)Added value of enhanced CT on LR-3 and LR-4 observation of Gd-EOB-DTPA MRI for the diagnosis of HCC: are CT and MR washout features interchangeable? Br J Radiol 95 20210738-410

[2] Kwon H(2019)LI-RADS v2014 categorization of hepatocellular carcinoma:intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI Eur Radiol 29 401-79

[3] Cho J(2020)Mitchell, Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging Hepatol Int 14 70-625

[4] Song JS(2015)Hepatobiliary agentsand their role in LI-RADS Abdom Imaging 40 613-863

[5] Choi EJ(2021)Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid–enhanced MRI Eur Radiol 31 855-128

[6] Hwang SB(2018)LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features Radiology 288 118-524

[7] Lee S(2018)Liver Imaging Reporting and Data System: patient outcomes for category 4 and 5 nodules Radiology 287 515-525

[8] Kim MJ(2021)LI-RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis J Magn Reson Imaging 54 518-79

[9] Kim SS(2020)Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging Hepatol Int 14 70-7801

[10] Hope TA(2019)Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging Eur Rev Med Pharmacol Sci 23 7786-345

[1] Lim K(2022)Added value of enhanced CT on LR-3 and LR-4 observation of Gd-EOB-DTPA MRI for the diagnosis of HCC: are CT and MR washout features interchangeable? Br J Radiol 95 20210738-410

[2] Kwon H(2019)LI-RADS v2014 categorization of hepatocellular carcinoma:intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI Eur Radiol 29 401-79

[3] Cho J(2020)Mitchell, Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging Hepatol Int 14 70-625

[4] Song JS(2015)Hepatobiliary agentsand their role in LI-RADS Abdom Imaging 40 613-863

[5] Choi EJ(2021)Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid–enhanced MRI Eur Radiol 31 855-128

[6] Hwang SB(2018)LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features Radiology 288 118-524

[7] Lee S(2018)Liver Imaging Reporting and Data System: patient outcomes for category 4 and 5 nodules Radiology 287 515-525

[8] Kim MJ(2021)LI-RADS Major Features on MRI for Diagnosing Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis J Magn Reson Imaging 54 518-79

[9] Kim SS(2020)Retrospective comparison of EASL 2018 and LI-RADS 2018 for the noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging Hepatol Int 14 70-7801

[10] Hope TA(2019)Critical analysis of major and ancillary features of LI-RADS v2018 in the differentiation of small (≤ 2 cm) hepatocellular carcinoma from dysplastic nodules with gadobenate dimeglumine-enhanced magnetic resonance imaging Eur Rev Med Pharmacol Sci 23 7786-345